Categories
Prostate cancer

Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones

  • Weiss L. Comments on hematogenous metastatic patterns in humans as revealed by autopsy. Clin Exp Metastasis. 1992;10:191–9.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, Kim SP, et al. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis. Prostate 2014;74:210–6.

    PubMed 
    Article 

    Google Scholar
     

  • Ashrafi AN, Fay C, Yip W, de Freitas DM, Nabhani J, Aron M. Durable biochemical response following adrenal metastasectomy for oligometastatic castrate-resistant prostate cancer. Urol Case Rep. 2020;32:101229.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S, et al. Rapid (“warm”) autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res. 2000;6:1038–45.

    CAS 
    PubMed 

    Google Scholar
     

  • Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006;66:2815–25.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Tamae D, Mostaghel E, Montgomery B, Nelson PS, Balk SP, Kantoff PW, et al. The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high-risk localized and advanced castration-resistant prostate cancer. Chem-Biol Interact. 2015;234:332–8.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl J Med. 2011;364:1995–2005.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Schiffer L, Barnard L, Baranowski ES, Gilligan LC, Taylor AE, Arlt W, et al. Human steroid biosynthesis, metabolism and excretion are differentially reflected by serum and urine steroid metabolomes: A comprehensive review. J Steroid Biochem Mol Biol. 2019;194:105439.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl J Med. 2014;371:424–33.

    PubMed 
    PubMed Central 
    Article 
    CAS 

    Google Scholar
     

  • Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N. Engl J Med. 2019;381:13–24.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl J Med. 2013;368:138–48.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl J Med. 2020;382:2091–102.

    PubMed 
    Article 

    Google Scholar
     

  • Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013;19:3621–30.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22:298–305.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell. 2017;32:474–89. e6.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science. 2017;355:84–8.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Boukovala M, Spetsieris N, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, et al. A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. Eur J Cancer 2020;127:67–75.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Spetsieris N, Boukovala M, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, et al. A Phase 2 trial of abiraterone followed by randomization to addition of Dasatinib or Sunitinib in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2021;19:22–31. e5.

    PubMed 
    Article 

    Google Scholar
     

  • Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinforma. 2009;25:1754–60.

    CAS 
    Article 

    Google Scholar
     

  • DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43:491–8.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31:213–9.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Ye K, Schulz MH, Long Q, Apweiler R, Ning Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinforma. 2009;25:2865–71.

    CAS 
    Article 

    Google Scholar
     

  • Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28:1747–56.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 2014;346:256–9.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics. 2004;5:557–72.

    PubMed 
    Article 

    Google Scholar
     

  • Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinforma. 2013;29:15–21.

    CAS 
    Article 

    Google Scholar
     

  • Anders S, Pyl PT, Huber W. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinforma. 2015;31:166–9.

    CAS 
    Article 

    Google Scholar
     

  • Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, et al. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol. 2015;67:53–60.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Efstathiou E, Titus M, Tsavachidou D, Tzelepi V, Wen S, Hoang A, et al. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol: Off J Am Soc Clin Oncol. 2012;30:637–43.

    CAS 
    Article 

    Google Scholar
     

  • Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res. 2005;11:4653–7.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Palanisamy N, Yang J, Shepherd PDA, Li-Ning-Tapia EM, Labanca E, Manyam GC, et al. The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) captures the molecular landscape of prostate cancer and facilitates Marker-driven therapy development. Clin Cancer Res. 2020;26:4933–46.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Varkaris A, Corn PG, Parikh NU, Efstathiou E, Song JH, Lee YC, et al. Integrating Murine and clinical trials with Cabozantinib to understand roles of MET and VEGFR2 as targets for growth inhibition of prostate cancer. Clin Cancer Res. 2016;22:107–21.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 2013;155:1309–22.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Isikbay M, Otto K, Kregel S, Kach J, Cai Y, Vander Griend DJ, et al. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Hormones Cancer. 2014;5:72–89.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Missaghian E, Kempná P, Dick B, Hirsch A, Alikhani-Koupaei R, Jégou B, et al. Role of DNA methylation in the tissue-specific expression of the CYP17A1 gene for steroidogenesis in rodents. J Endocrinol. 2009;202:99–109.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Perkins LM, Payne AH. Quantification of P450scc, P450(17) alpha, and iron sulfur protein reductase in Leydig cells and adrenals of inbred strains of mice. Endocrinology 1988;123:2675–82.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA. 2019;116:11428–36.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Armstrong AJ, Halabi S, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, et al. Prospective multicenter validation of androgen receptor Splice Variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: The PROPHECY Study. J Clin Oncol: Off J Am Soc Clin Oncol. 2019;37:1120–9.

    CAS 
    Article 

    Google Scholar
     

  • Mostaghel EA, Zhang A, Hernandez S, Marck BT, Zhang X, Tamae D, et al. Contribution of adrenal glands to intratumor androgens and growth of castration-resistant prostate cancer. Clin Cancer Res. 2019;25:426–39.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Mostaghel EA, Marck BT, Kolokythas O, Chew F, Yu EY, Schweizer MT, et al. Circulating and intratumoral adrenal androgens correlate with response to abiraterone in men with castration-resistant prostate cancer. Clin Cancer Res. 2021;27:6001–11.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Aparicio AM, Shen L, Tapia EL, Lu JF, Chen HC, Zhang J, et al. Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers. Clin Cancer Res. 2016;22:1520–30.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68:4447–54.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus Prednisone in metastatic, castration-sensitive prostate cancer. N. Engl J Med. 2017;377:352–60.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Evaul K, Li R, Papari-Zareei M, Auchus RJ, Sharifi N. 3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer. Endocrinology 2010;151:3514–20.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Efstathiou E, Davis JW, Pisters L, Li W, Wen S, McMullin RP, et al. Clinical and biological characterisation of localised high-risk prostate cancer: results of a randomised preoperative study of a luteinising hormone-releasing hormone agonist with or without Abiraterone Acetate plus Prednisone. Eur Urol. 2019;76:418–24.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar